Analysis of Clinical Features of Chronic Liver Disease Complicated With Hepatopulmonary Syndrome

NCT05932927 | Unknown

• 1 other identifier: 2022-096
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Hepatopulmonary syndrome (HPS) has unknown pathogenesis, limited treatment and poor prognosis. The onset of HPS is insidious and easy to be ignored. Many liver diseases such as "cirrhosis and related complications" are the core characteristics of Beijing You 'an Hospital, but the clinical characteristics of HPS patients in the center are still unclear. The investigators plan to make the diagnosis of HPS among chronic liver disease patients in the hospital according to the diagnostic criteria of HPS proposed in the Practice Guidelines of the International Society of Liver Transplantation in 2016, collect clinical data of HPS participants, evaluate the severity, analyze and summarize clinical characteristics, and conduct management and follow-up. At the same time, The investigators collect blood samples for proteomics tests. In order to improve the diagnosis and treatment level of HPS.

Conditions

Hepatopulmonary Syndrome (HPS)

Outcome Measures

Primary Outcomes (1)

• Proteomic results of participants

  Qualitative and quantitative analysis of proteome

  April 1,2024

Study Arms (2)

Chronic liver disease with hepatopulmonary syndrome

Liver disease (usually cirrhosis with portal hypertension) ；Positive CE-TTE（Contrast enhanced contrast ultrasound）；Abnormal arterial oxygenation: Alveolar-arterial oxygen gradient (AaO2) ≥ 15 mm Hg (\>20 mm Hg if age \> 64)

Biological: Proteomic sequencing

Chronic liver disease without hepatopulmonary syndrome

Liver disease (usually cirrhosis with portal hypertension) ； Negative CE-TTE

Biological: Proteomic sequencing

Interventions

Proteomic sequencing BIOLOGICAL

Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups

Chronic liver disease with hepatopulmonary syndrome; Chronic liver disease without hepatopulmonary syndrome

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with chronic liver disease admitted to You 'an Hospital.

You may qualify if:

• chronic hepatitis Agreed to venous blood collection

You may not qualify if:

• pneumonia, pulmonary vascular disease, interstitial pulmonary disease, COPD, bronchial asthma, lung cancer and other primary pulmonary diseases, acute upper gastrointestinal bleeding.

Sponsors & Collaborators

• Sun Jie: lead

Study Sites (1)

No.8, Xitoutiao, Youan Men Wai, Fengtai District

Beijing, 100038, China

RECRUITING

MeSH Terms

Conditions

Hepatopulmonary Syndrome

Condition Hierarchy (Ancestors)

Liver Diseases; Digestive System Diseases; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: June 9, 2023
• First Posted: July 6, 2023
• Study Start: April 1, 2023
• Primary Completion: April 1, 2024
• Study Completion: June 1, 2024
• Last Updated: July 6, 2023

Record last verified: 2023-07

Locations

CN (1)